Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given a consensus rating of “Moderate Buy” by the seventeen research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $110.91.

Several research firms have weighed in on GPCR. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Citizens Jmp restated a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research note on Wednesday, September 9th. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC lifted its stake in Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after purchasing an additional 1,150,000 shares during the last quarter. Capitolis Liquid Global Markets LLC purchased a new stake in Structure Therapeutics in the 4th quarter worth approximately $61,086,000. Principal Financial Group Inc. lifted its stake in Structure Therapeutics by 36.6% in the first quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock worth $84,531,000 after acquiring an additional 469,554 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Structure Therapeutics in the 4th quarter worth about $32,535,000. Finally, EcoR1 Capital LLC bought a new stake in Structure Therapeutics during the 4th quarter valued at approximately $23,256,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 4.3%

GPCR stock opened at $31.27 on Friday. The firm has a market capitalization of $2.18 billion, a PE ratio of -31.27 and a beta of -1.45. The stock’s 50 day moving average is $45.54 and its 200-day moving average is $46.09. Structure Therapeutics has a twelve month low of $25.59 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts anticipate that Structure Therapeutics will post -1.87 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.